Efficacy and safety of oral semaglutide versus placebo in subjects with type 2 diabetes mellitus treated with diet and exercise only. A 26-week, randomised, double-blind, placebo-controlled trial
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Jun 2017
At a glance
- Drugs Semaglutide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 1 - Monotherapy
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 23 May 2017 Planned End Date changed from 27 Nov 2017 to 9 Dec 2017.
- 23 May 2017 Planned primary completion date changed from 27 Nov 2017 to 26 Nov 2017.